Prominent Players in the Taiwan Angina Market | Insights & Companies 2026

Prominent Players in the Taiwan Angina Market

Taiwan Angina Market is curated by a combination of major global players and domestic producers, each vying for a higher market share through product innovation and promotion of sustainable practices. Major companies in the market include Novartis (Taiwan), AstraZeneca Taiwan, Sanofi-Aventis Taiwan, and Standard Chemical & Pharmaceutical Co., Ltd.

Taiwan Angina Market Overview

According to 6Wresearch, the Taiwan angina market is poised for steady growth, determined by its versatile applications across the healthcare sector, including cardiology, emergency medicine, and chronic disease management. The market is particularly influenced by the increasing demand for natural and patient-centric treatment methods, as consumers focus towards effective oral therapies and life-saving interventions in personal care and home-based recovery.

Generally, angina products are specialized medical tools designed to manage the symptoms and underlying causes of chest pain resulting from reduced blood flow to the heart. These products appear as nitrate sprays, beta-blockers, calcium channel blockers, or advanced drug-eluting stents and are used extensively in clinical and homecare applications due to their myocardial oxygen demand reduction properties.

Competitive Landscape

The competitive landscape of the Taiwan angina industry is specified by the presence of several global giants, regional producers, and a rising number of emerging companies. Leading players have a significant market share due to their longstanding presence in the pharmaceutical and medical device industries. They invest greatly towards research and development (R&D) to innovate and develop smart delivery systems and eco-friendly products to satisfy the increasing consumer demand for improved patient compliance.

Below is a list of leading players operating in the Taiwan Angina Market:

1. Novartis (Taiwan)

Novartis is a major player in Taiwan's cardiovascular sector, providing essential treatments like Entresto and Exforge that manage hypertension.

2. AstraZeneca Taiwan

AstraZeneca maintains a high share through cardiovascular and metabolic research, offering a broad portfolio of anti-platelet and lipid-lowering therapies.

3. Sanofi-Aventis Taiwan

Sanofi is a leader in chronic disease management, offering specialized medications that target cardiovascular risk factors and acute coronary syndromes.

4. Standard Chemical & Pharmaceutical Co., Ltd.

Standard Chemical offers a wide array of affordable cardiovascular generics, like beta-blockers and nitrates, which manage angina symptoms.

5. Synmosa Biopharma Corporation

Synmosa is a pioneer in specialized drug delivery, providing various cardiovascular treatments and respiratory products that support heart health.

6. TTY Biopharm Company Limited

TTY Biopharm specializes in high-barrier generics and innovative formulations, ensuring high-quality cardiovascular treatment options.

7. Lotus Pharmaceutical Co., Ltd.

Lotus is recognized for its high-quality generic portfolio and strategic partnerships, frequently providing essential anti-anginal medications in hospital settings.

8. Orient EuroPharma Co., Ltd. (OEP)

OEP provides a diverse range of pharmaceuticals, focusing on metabolic and cardiovascular health through the distribution of innovative international brands.

9. Bayer Taiwan

Bayer is a leading provider of anti-thrombotic therapies and cardiovascular preventatives, focusing on long-term management of coronary artery disease.

10. China Chemical & Pharmaceutical Co., Ltd. (CCPC)

CCPC produces a variety of essential medicines, including calcium channel blockers and other anti-hypertensive agents used in angina management.

Prominent Players in the Taiwan Angina Market: FAQs